|
Eine Ebene nach oben |
Gruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 13
Zeitschriftenartikel
Hayden, P. J.; Roddie, C.; Bader, P.; Basak, G. W.; Bonig, H.; Bonini, C.; Chabannon, C.; Ciceri, F.; Corbacioglu, S.; Ellard, R.; Sanchez-Guijo, F.; Jaeger, U.; Hildebrandt, M.; Hudecek, M.; Kersten, M. J.; Koehl, U.; Kuball, J.; Mielke, S.; Mohty, M.; Murray, J.; Nagler, A.; Rees, J.; Rioufol, C.; Saccardi, R.; Snowden, J. A.; Styczynski, J.; Subklewe, M.; Thieblemont, C.; Topp, M.; Ispizua, A. U.; Chen, D.; Vrhovac, R.; Gribben, J. G.; Kroeger, N.; Einsele, H. und Yakoub-Agha, I
(2022):
Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA).
In: Annals of Oncology, Bd. 33, Nr. 3: S. 259-275
Bishop, M. R.; Dickinson, M.; Purtill, D.; Barba, P.; Santoro, A.; Hamad, N.; Kato, K.; Sureda, A.; Greil, R.; Thieblemont, C.; Morschhauser, F.; Janz, M.; Flinn, I.; Rabitsch, W.; Kwong, Y.-L.; Kersten, M. J.; Minnema, M. C.; Holte, H.; Chan, E. H. L.; Martinez-Lopez, J.; Mueller, A. M. S.; Maziarz, R. T.; McGuirk, J. P.; Bachy, E.; Le Gouill, S.; Dreyling, M.; Harigae, H.; Bond, D.; Andreadis, C.; McSweeney, P.; Kharfan-Dabaja, M.; Newsome, S.; Degtyarev, E.; Awasthi, R.; del Corral, C.; Andreola, G.; Masood, A.; Schuster, S. J.; Jaeger, U.; Borchmann, P. und Westin, J. R.
(2021):
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.
In: New England Journal of Medicine, Bd. 386, Nr. 7: S. 629-639
Rule, S.; Jurczak, W.; Jerkeman, M.; Rusconi, C.; Trneny, M.; Offner, F.; Caballero, D.; Joao, C.; Witzens-Harig, M.; Hess, G.; Bence-Bruckler, I.; Cho, S-G; Thieblemont, C.; Zhou, W.; Henninger, T.; Goldberg, J.; Vermeulen, J. und Dreyling, M.
(2018):
Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study.
In: Leukemia, Bd. 32, Nr. 8: S. 1799-1803
Dreyling, M.; Morschhauser, F.; Bouabdallah, K.; Bron, D.; Cunningham, D.; Assouline, S. E.; Verhoef, G.; Linton, K.; Thieblemont, C.; Vitolo, U.; Hiemeyer, F.; Giurescu, M.; Garcia-Vargas, J.; Gorbatchevsky, I.; Liu, L.; Koechert, K.; Pena, C.; Neves, M.; Childs, B. H. und Zinzani, P. L.
(2017):
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.
In: Annals of Oncology, Bd. 28, Nr. 9: S. 2169-2178
Jerkeman, M.; Hallek, M.; Dreyling, M.; Thieblemont, C.; Kimby, E. und Staudt, L.
(2017):
Targeting of B-cell receptor signalling in B-cell malignancies.
In: Journal of internal Medicine, Bd. 282, Nr. 5: S. 415-428
Younes, A.; Hilden, P.; Coiffier, B.; Hagenbeek, A.; Salles, G.; Wilson, W.; Seymour, J. F.; Kelly, K.; Gribben, J.; Pfreunschuh, M.; Morschhauser, F.; Schoder, H.; Zelenetz, A. D.; Rademaker, J.; Advani, R.; Valente, N.; Fortpied, C.; Witzig, T. E.; Sehn, L. H.; Engert, A.; Fisher, R. I.; Zinzani, P.-L.; Federico, M.; Hutchings, M.; Bollard, C.; Trneny, M.; Elsayed, Y. A.; Tobinai, K.; Abramson, J. S.; Fowler, N.; Goy, A.; Smith, M.; Ansell, S.; Kuruvilla, J.; Dreyling, M.; Thieblemont, C.; Little, R. F.; Aurer, I.; Oers, M. H. J. van; Takeshita, K.; Gopal, A.; Rule, S.; Vos, S. de; Kloos, I.; Kaminski, M. S.; Meignan, M.; Schwartz, L. H.; Leonard, J. P.; Schuster, S. J. und Seshan, V. E.
(2017):
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).
In: Annals of Oncology, Bd. 28, Nr. 7: S. 1436-1447
Hoster, Eva; Rosenwald, Andreas; Berger, F.; Bernd, Heinz Wolfram; Hartmann, S.; Loddenkemper, Christoph; Barth, Thomas E. F.; Brousse, N.; Pileri, S.; Rymkiewicz, G.; Kodet, Roman; Stilgenbauer, S.; Forstpointner, R.; Thieblemont, C.; Hallek, M.; Coiffier, B.; Vehling-Kaiser, U.; Bouabdallah, R.; Kanz, L.; Pfreundschuh, M.; Schmidt, C.; Ribrag, Vincent; Hiddemann, Wolfgang; Unterhalt, Michael; Kluin-Nelemans, J. C.; Hermine, Olivier; Dreyling, Martin und Klapper, Wolfram
(2016):
Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.
In: Journal of Clinical Oncology, Bd. 34, Nr. 12: S. 1386-1394
Hermine, Olivier; Hoster, Eva; Walewski, J.; Bosly, A.; Stilgenbauer, S.; Thieblemont, C.; Szymczyk, Michal; Bouabdallah, R.; Kneba, M.; Hallek, M.; Salles, G.; Feugier, P.; Ribrag, Vincent; Birkmann, J.; Forstpointner, R.; Haioun, C.; Hänel, M.; Casasnovas, R. O.; Finke, J.; Peter, N.; Bouabdallah, K.; Sebban, C.; Fischer, T.; Dührsen, U.; Metzner, B.; Maschmeyer, G.; Kanz, L.; Schmidt, C.; Delarue, R.; Brousse, N.; Klapper, Wolfram; Macintyre, E.; Delfau-Larue, M. H.; Pott, Christiane; Hiddemann, Wolfgang; Unterhalt, Michael und Dreyling, Martin
(2016):
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.
In: Lancet, Bd. 388, Nr. 10044: S. 565-575
Dreyling, M. H.; Morschhauser, F.; Bouabdallah, K.; Cunningham, D.; Bron, D.; Linton, K.; Assouline, S.; Verhoef, G.; Thieblemont, C.; Vitolo, U.; Garcia-Vargas, J.; Gorbatchevsky, I; Neves, M.; Grunert, J.; Hiemeyer, F.; Childs, B. H. und Zinzani, P. L.
(2016):
Phase 2a study of the phosphatidylinositol-3-kinase (PI3K) inhibitor copanlisib in patients with relapsed/refractory, indolent or aggressive lymphoma.
In: Oncology Research and Treatment, Bd. 39: S. 310
Dreyling, M.; Morschhauser, F.; Bouabdallah, K.; Cunningham, D.; Bron, D.; Linton, K.; Assouline, S.; Verhoef, G.; Thieblemont, C.; Vitolo, U.; Garcia-Vargas, J.; Gorbatchevsky, I.; Neves, M.; Grunert, J.; Hiemeyer, F.; Childs, B. H. und Zinzani, P. L.
(2016):
Phase 2a study of the Phosphatidylinositol-3-Kinase (PI3K) inhibitor Copanlisib in patients with relapsed/refractory, indolent or aggressive lymphoma.
In: Haematologica, Bd. 101: S. 104
Delfau-Larue, M. H.; Klapper, Wolfram; Berger, F.; Jardin, F.; Briere, J.; Salles, G.; Casasnovas, O.; Feugier, P.; Haioun, C.; Ribrag, Vincent; Thieblemont, C.; Unterhalt, Michael; Dreyling, Martin; Macintyre, E.; Pott, Christiane; Hermine, Olivier und Hoster, Eva
(2015):
High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma.
In: Blood, Bd. 126, Nr. 5: S. 604-611
Cheminant, M.; Derrieux, C.; Touzart, A.; Schmit, S.; Grenier, A.; Trinquand, A.; Delfau-Larue, M. H.; Lhermitte, L.; Thieblemont, C.; Ribrag, Vincent; Cheze, S.; Sanhes, L.; Jardin, F.; Lefrere, F.; Delarue, R.; Hoster, Eva; Dreyling, Martin; Asnafi, V.; Hermine, Olivier und Macintyre, E.
(2015):
Minimal Residual Disease monitoring by 8-color flow cytometry in Mantle Cell Lymphoma: an EU-MCL and LYSA study.
In: Haematologica, Bd. 101, Nr. 3: S. 336-345
Kluin-Nelemans, H. C.; Hoster, Eva; Hermine, Olivier; Walewski, J.; Trneny, Marek; Geisler, C. H.; Stilgenbauer, S.; Thieblemont, C.; Vehling-Kaiser, U.; Doorduijn, J. K.; Coiffier, B.; Forstpointner, R.; Tilly, H.; Kanz, L.; Feugier, P.; Szymczyk, Michal; Hallek, M.; Kremers, S.; Lepeu, G.; Sanhes, L.; Zijlstra, J. M.; Bouabdallah, R.; Lugtenburg, P. J.; Macro, M.; Pfreundschuh, M.; Prochazka, V.; Di Raimondo, F.; Ribrag, Vincent; Uppenkamp, M.; Andre, M.; Klapper, Wolfram; Hiddemann, Wolfgang; Unterhalt, Michael und Dreyling, Martin
(2012):
Treatment of older patients with mantle-cell lymphoma.
In: New England Journal of Medicine / NEJM, Bd. 367, Nr. 6: S. 520-531